SECALITS

European Group For Accreditation And Liaison Of Blood-Tissues And Cells Establishments

EU4Health Web-InfoDay 2024

Mag. Dr. Simone Hennerbichler-Lugscheider



This presentation is part of the project / joint action '101056852/EGALITE' which has received funding from the European Union's Health Programme (2014-2020). The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be considered to reflect the views of the European Commission and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information





BLUTZENTRALE LINZ

BLOOD PRODUCTS + MEDICINAL PRODUCTS



clean rooms for separation of blood components (GMP class D)





CELL AND TISSUE PRODUCTS



Cornea, DMEK, sclera



Heart valve and aorta



Amnion







Plasma Erythrocytes Thrombocytes Serum eye drops + medicinal products + ATMPs for clinical studies

Cranial bone

Ovarian tissue



Peripheral blood stem cells

- 2022:
- ~ 53.000 blood donations
- ~ 3.500 apheresis
- ~ 570 tissue donations (allogeneic + autologous)



OTHER AREAS:

- Blood + tissue donation
- Outpatient clinics
- Hematology, Coagulation, Immunhematology
- PCR- and ELISAscreening of products and patient samples
- Microbiology, Immunogenetics, Immunology
- R&D: Tissue Regeneration with LBI Trauma



Co-funded by: the headby Programme the headby Programme to the Groupwant Ninno Considered to reflect the views of the author only and is his/her sole responsibility; it can not be the Groupwant Ninno Considered to reflect the views of the European Commission and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information



it contains.



Substances of Human Origin (SoHO)

Setting standards to save lives

Blood, tissues, cells and organs are used in a variety of medical therapies. J based on these substances of human origin (SoHO) save lives (e.g. blood tra case of trauma), improve the quality of life (e.g. kidney transplants), and ever life (gametes and in vitro fertilisation). Despite their benefits, the use of S risks, in particular the transmission of diseases. The European Commissi these risks through its mandate to set high standards of quality and safets with Art. L68(4)(a) of the Treaty on the functioning of the EU. To this end including drafting legislation and developing guidance, assisting national accompanied by vigilance activities and project support. The overall object



https://health.ec.europa.eu/blood-tissues-cells-and-organs/overview/proposal-regulation-substances-human-origin_e

🌐 English

Search

Public Health

European

Commission

Home > Blood, tissues, cells and organs > Overview > New EU rules on substances of human origin

New EU rules on substances of human origin

PAGE CONTENTS

Commission proposal

Next steps

Latest updates

Documents

On 14 December 2023, a political agreement was reached on the Commission's proposal for a Regulation on standards of quality and safety for substances of human origin intended for human application.

Press release ()

<u>Factsheet</u> (6)

The agreed text m, prior to legal-linguistic revision, is available on the Council website.

The Commission Proposal @, was tabled in July 2022.

- Press release .
- <u>MEMO</u> ,

The new EU rules, which should now be endorsed in the course of 2024

- support the continued provision of SoHO therapies, now and in the future, based on high safety and quality standards and up-to-date technical rules
- extend protective measures to new groups of patients, to donors and to offspring born from medically assisted reproduction
- improve harmonisation across Member States, facilitating cross-border exchange of SoHO and improving patient access to the therapies they need
- create conditions for safe, effective and accessible innovation in a unique sector driven by public health services and voluntary and unpaid donations
- · improve crisis preparedness and resilience to safeguard access to therapies
- · implement digital-ready policies
- contribute to the European Health Union by pooling of technical expertise and achieving
 economies of scale.

As the Directives it repeals, the proposed Regulation has Article 168(4)(a) of the Treaty on the Functioning of the European Union as its legal basis. Feedback on the proposal was collected from 14 July 2022 to 08 September 2022 on the <u>Have your Say Portal</u> .



-Lugscheider

GECALITE

/her sole responsibility; it can not be use that may be made of the information







Blood, Tissues and HSC



Consortium of 25 Organizations

(Beneficiaries + External Experts)



in the service when the





European Accreditation Program

as a means to achieve mutual recognition amongst SoHO organisations. Optimize resources and improve collaboration

Definition of strategies to promote self sufficiency in the EU.

Enhancing the ability of SoHO organisations to respond during crisis Ensure supply of essential SoHO in routine and during crisis, and define technical assistance programs

G ECALIT3

This presentation is part of the project / joint action '101056852/EGALITE' which has received funding from the European Union's Health Programme (2014-2020). The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be







10 Member States

- Blood and Tissue Establishments
- Competent Authorities
- Scientific Societies

Co-funded by the Health Programme of the European Union



This presentation is part of the project / joint action '101056852/EGALITE' which has received funding from the European Union's Health Programme (2014-2020). The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be considered to reflect the views of the European Commission and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information



External Experts from 10 Organisations





Car-lunded by: the Health Programme of the European Commission and the Agency do not accept any responsibility for use that may be made of the information





WP1	Management and Coordination of the Project	Banc de Sang i Teixits	Spain
WP2	Dissemination & Communication		Greece
WP3	Evaluation	ST Instance Portugate ST Instance Portugate Descriptions	Portugal + Italy
WP4	Integration and sustainability	MONT	Spain
WP5	EGALITE Accreditation Program	EBMT BANC DE SANG	EU + Spain
WP6	BTC Database		Germany
WP7	Contingency plans	ETR ISG. FE	Netherlands
WP8	Develop of European Assistance Mechanisms	OSTERREICHISCHES ROTES KREUZ	Austria





European Accrediation Program WP5

Harmonisation/ mutual recognition



Establish EGALiTE

- practical procedures, rules and by-laws
- Accreditation guide
- long-term sustainability



Establish a Network

- potential auditees
- potential collaborators



Audit guidance and harmonized report templates and procedures



Face-to-face programmes and E-learning Platform to facilitate future EU Training Potential auditor







BTC Database WP6

Optimize resources and improve collaboration



BTC Database

Activities and Preparation Processes Facilities and equipment available Ability to process for 3rd parties Sufficiency levels Accreditation status Access to donors/donation centers Etc.



Map of Resources (will allow the visualization of the resources currently available in the different Member States)

GECALITE





Contingency Plans WP7

Enhancing the ability of SoHO organisations to respond during crisis



- Contingency Plans: action plans which shall be activated in case of the different scenarios of crisis.
 - Tools
 - Guidance

A funded by the factor of the project / joint action '101056852/EGALITE' which has received funding from the European Union's Health Programme (2014-2020). The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be the terropean Union's Health Programme (2014-2020). The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be the terropean Union's Health Programme (2014-2020). The content of this presentation represents the views of the European Commission and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information



Technical Assistance Programme WP8

Implementation and optimization of good practices



Technical Assistance Programme (propose the mechanisms to fund and coordinate the participation of EGALITE accredited experts in the activities requested by Procurement Organisations/donation centers, Blood and Tissue Establishments, Hospital Blood Banks, and Competent Authorities of any European Member State)

- workshops, congresses
- Study visits
- Expert missions

This presentation is part of the project / joint action '101056852/EGALITE' which has received funding from the European Union's Health Programme (2014-2020). The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be the two of the function '101056852/EGALITE' which has received funding from the European Union's Health Programme (2014-2020). The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be the two of the information.

EGALiTE status

- EGALITE's Accreditation Process (scope, tools, auditors and other requirements)
- EGALITE's Accreditation Guide + Standards (based on EDQM Guides and other references)
- Specifications and requirements of the new BTC Database
- Technical Assistance Programme (TAP)
- Tools and guidance for the Contingency Plans
- Sustainability plan for project outcome and take-over by scientific societies (EEBA and EATCB)

Made by a main brown of the project / joint action '101056852/EGALITE' which has received funding from the European Union's Health Programme (2014-2020). The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be considered to reflect the views of the European Commission and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information





THANKS!

Any questions?

- <u>dissemination@egalite-europe.eu</u>
- www.egalite-europe.eu/



co-funded by many the European Union's Health Programme (2014-2020). The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be the European Union's Health Programme (2014-2020). The content of this presentation represents the views of the European Commission and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information

